Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndromeCentral MessagePerspective

Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndromeCentral MessagePerspective

Objective: To assess the safety and feasibility of low-dose, novel, allogenic mesenchymal precursor cell (MPC) therapy as an adjunct to left ventricular (LV) recruitment for patients with hypoplastic left heart syndrome (HLHS) and borderline left ventricles. MPC injections into the hypoplastic left...

Full description

Bibliographic Details
Main Authors: Rachel E. Wittenberg, BS, Kimberlee Gauvreau, ScD, Jonah Leighton, CST, Melinda Moleon-Shea, BS, Kenneth M. Borow, MD, Gerald R. Marx, MD, Sitaram M. Emani, MD
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:JTCVS Open
Subjects:
hypoplastic left heart syndrome
biventricular conversion
left ventricular recruitment
stem cell therapy
congenital heart disease
regenerative medicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2666273623003042

Internet

http://www.sciencedirect.com/science/article/pii/S2666273623003042

Similar Items